MedTrace Logo

Effectiveness and Safety of Firmagon® in Androgen Ablative Therapy of Advanced Hormone-dependent Prostate Carcinoma in Argentina

NCT01861236 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 90

Last updated 2018-10-23

No results posted yet for this study

Summary

Prospective, observational study to collect and analyze data on patients with advanced hormone dependent prostate cancer treated with Firmagon® according to routine medical practice in Argentina

Conditions

  • Advanced Hormone Dependent Prostate Cancer

Interventions

DRUG

Firmagon® (degarelix)

Monthly subcutaneous injections

Sponsors & Collaborators

  • Ferring Pharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Clinical Development Support · Ferring Pharmaceuticals

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-03-31
Primary Completion
2018-09-03
Completion
2018-09-03

Countries

  • Argentina

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01861236 on ClinicalTrials.gov